newsfilter
← Latest News
PR Newswire·

Theseus Pharmaceuticals Announces First Patient Treated with THE-630 in Phase 1/2 Study in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)

CAMBRIDGE, Mass., Jan. 10, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (Theseus) (NASDAQ:THRX), a clinical stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization